Phase II clinical trials of BCNU (NSC 409962) and bleomcyin (NSC 125066) in the treatment of Kaposi's sarcoma

Charles Vogel, D. Clements, A. K. Wanume, T. Toya, A. Primack, S. Kyalwazi

Research output: Chapter in Book/Report/Conference proceedingChapter

23 Citations (Scopus)

Abstract

Phase II clinical trials of 1,3 bis 2 chloroethyl 1 nitrosourea (BCNU) and bleomycin were done in patients with Kaposi's sarcoma. Objective antitumor responses were seen in 9 of 21 patients (43%) treated with BCNU and 6 of 10 (60%) treated with bleomycin. Responses to BCNU were more complete and durable than the responses to bleomycin. BCNU toxic effects at dose levels of 200 mg/m 2 (repeated every 6-8 wk) were tolerable; however, there was one drug related death in a patient who received higher dose levels. Bleomycin given at a total dose of 300 mg over a 1 mth period was well tolerated; however, one patient treated with 600 mg died of pulmonary fibrosis. Several agents, including BCNU, bleomycin, 5 3,3 dimethyl 1 triazeno imidazole 4 carboxamide, vincristine, and actinomycin D, have now been shown to be effective against Kaposi's sarcoma. It is hoped that various combinations of these agents can be used to obtain more complete control of this disease in Uganda where radiation therapy is not yet available.

Original languageEnglish
Title of host publicationCANCER CHEMOTHER.REP.
Pages325-333
Number of pages9
Volume57
Edition3
StatePublished - Dec 1 1973
Externally publishedYes

Fingerprint

Phase II Clinical Trials
Kaposi's Sarcoma
Bleomycin
Therapeutics
Carmustine
Dacarbazine
Uganda
Pulmonary Fibrosis
Poisons
Dactinomycin
Vincristine
Radiotherapy
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Vogel, C., Clements, D., Wanume, A. K., Toya, T., Primack, A., & Kyalwazi, S. (1973). Phase II clinical trials of BCNU (NSC 409962) and bleomcyin (NSC 125066) in the treatment of Kaposi's sarcoma. In CANCER CHEMOTHER.REP. (3 ed., Vol. 57, pp. 325-333)

Phase II clinical trials of BCNU (NSC 409962) and bleomcyin (NSC 125066) in the treatment of Kaposi's sarcoma. / Vogel, Charles; Clements, D.; Wanume, A. K.; Toya, T.; Primack, A.; Kyalwazi, S.

CANCER CHEMOTHER.REP.. Vol. 57 3. ed. 1973. p. 325-333.

Research output: Chapter in Book/Report/Conference proceedingChapter

Vogel, C, Clements, D, Wanume, AK, Toya, T, Primack, A & Kyalwazi, S 1973, Phase II clinical trials of BCNU (NSC 409962) and bleomcyin (NSC 125066) in the treatment of Kaposi's sarcoma. in CANCER CHEMOTHER.REP.. 3 edn, vol. 57, pp. 325-333.
Vogel C, Clements D, Wanume AK, Toya T, Primack A, Kyalwazi S. Phase II clinical trials of BCNU (NSC 409962) and bleomcyin (NSC 125066) in the treatment of Kaposi's sarcoma. In CANCER CHEMOTHER.REP.. 3 ed. Vol. 57. 1973. p. 325-333
Vogel, Charles ; Clements, D. ; Wanume, A. K. ; Toya, T. ; Primack, A. ; Kyalwazi, S. / Phase II clinical trials of BCNU (NSC 409962) and bleomcyin (NSC 125066) in the treatment of Kaposi's sarcoma. CANCER CHEMOTHER.REP.. Vol. 57 3. ed. 1973. pp. 325-333
@inbook{5fcb6ed220954593b25f1634676d5a92,
title = "Phase II clinical trials of BCNU (NSC 409962) and bleomcyin (NSC 125066) in the treatment of Kaposi's sarcoma",
abstract = "Phase II clinical trials of 1,3 bis 2 chloroethyl 1 nitrosourea (BCNU) and bleomycin were done in patients with Kaposi's sarcoma. Objective antitumor responses were seen in 9 of 21 patients (43{\%}) treated with BCNU and 6 of 10 (60{\%}) treated with bleomycin. Responses to BCNU were more complete and durable than the responses to bleomycin. BCNU toxic effects at dose levels of 200 mg/m 2 (repeated every 6-8 wk) were tolerable; however, there was one drug related death in a patient who received higher dose levels. Bleomycin given at a total dose of 300 mg over a 1 mth period was well tolerated; however, one patient treated with 600 mg died of pulmonary fibrosis. Several agents, including BCNU, bleomycin, 5 3,3 dimethyl 1 triazeno imidazole 4 carboxamide, vincristine, and actinomycin D, have now been shown to be effective against Kaposi's sarcoma. It is hoped that various combinations of these agents can be used to obtain more complete control of this disease in Uganda where radiation therapy is not yet available.",
author = "Charles Vogel and D. Clements and Wanume, {A. K.} and T. Toya and A. Primack and S. Kyalwazi",
year = "1973",
month = "12",
day = "1",
language = "English",
volume = "57",
pages = "325--333",
booktitle = "CANCER CHEMOTHER.REP.",
edition = "3",

}

TY - CHAP

T1 - Phase II clinical trials of BCNU (NSC 409962) and bleomcyin (NSC 125066) in the treatment of Kaposi's sarcoma

AU - Vogel, Charles

AU - Clements, D.

AU - Wanume, A. K.

AU - Toya, T.

AU - Primack, A.

AU - Kyalwazi, S.

PY - 1973/12/1

Y1 - 1973/12/1

N2 - Phase II clinical trials of 1,3 bis 2 chloroethyl 1 nitrosourea (BCNU) and bleomycin were done in patients with Kaposi's sarcoma. Objective antitumor responses were seen in 9 of 21 patients (43%) treated with BCNU and 6 of 10 (60%) treated with bleomycin. Responses to BCNU were more complete and durable than the responses to bleomycin. BCNU toxic effects at dose levels of 200 mg/m 2 (repeated every 6-8 wk) were tolerable; however, there was one drug related death in a patient who received higher dose levels. Bleomycin given at a total dose of 300 mg over a 1 mth period was well tolerated; however, one patient treated with 600 mg died of pulmonary fibrosis. Several agents, including BCNU, bleomycin, 5 3,3 dimethyl 1 triazeno imidazole 4 carboxamide, vincristine, and actinomycin D, have now been shown to be effective against Kaposi's sarcoma. It is hoped that various combinations of these agents can be used to obtain more complete control of this disease in Uganda where radiation therapy is not yet available.

AB - Phase II clinical trials of 1,3 bis 2 chloroethyl 1 nitrosourea (BCNU) and bleomycin were done in patients with Kaposi's sarcoma. Objective antitumor responses were seen in 9 of 21 patients (43%) treated with BCNU and 6 of 10 (60%) treated with bleomycin. Responses to BCNU were more complete and durable than the responses to bleomycin. BCNU toxic effects at dose levels of 200 mg/m 2 (repeated every 6-8 wk) were tolerable; however, there was one drug related death in a patient who received higher dose levels. Bleomycin given at a total dose of 300 mg over a 1 mth period was well tolerated; however, one patient treated with 600 mg died of pulmonary fibrosis. Several agents, including BCNU, bleomycin, 5 3,3 dimethyl 1 triazeno imidazole 4 carboxamide, vincristine, and actinomycin D, have now been shown to be effective against Kaposi's sarcoma. It is hoped that various combinations of these agents can be used to obtain more complete control of this disease in Uganda where radiation therapy is not yet available.

UR - http://www.scopus.com/inward/record.url?scp=0015857645&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0015857645&partnerID=8YFLogxK

M3 - Chapter

VL - 57

SP - 325

EP - 333

BT - CANCER CHEMOTHER.REP.

ER -